The Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins, CHMP/BMWP/42832/2005 laid down general recommendations for the performance of a systematic immunogenicity assessment from a marketing authorisation perspective.

 

Posted on the EMA website on 25 March 2014